Clinical trials: Juvenile Absence Epilepsy
Childhood Absence Epilepsy
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
The primary purpose of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in pediatric participants with treatment-resistant childhood absence seizures.
- Trial name
- NCT03355300
- Testing
- Cannabidiol Oral Solution
- Where
- 9 sites in United States
- Volunteers
- 11 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Childhood Absence Epilepsy, Petit Mal Epilepsy
Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study
The purpose of this study is to determine the best initial treatment for childhood absence epilepsy.
- Conditions
- Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
- Trial name
- NCT00088452
- Testing
- Ethosuximide, Lamotrigine, Valproic acid
- Where
- 31 sites in United States
- Volunteers
- 453 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Childhood Absence Epilepsy, Juvenile Absence Epilepsy
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
- Trial name
- NCT05109234
- Testing
- Brivaracetam Film-coated tablet, Brivaracetam oral solution
- Where
- 24 sites in United States, Georgia and 4 more
- Volunteers
- 84 people
- Sponsor
- UCB Biopharma SRL
Childhood Absence Epilepsy
Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
The primary purpose of this study is to assess the efficacy of Cannabidiol Oral Solution in the treatment of pediatric participants with treatment-resistant childhood absence seizures.
- Trial name
- NCT03336242
- Testing
- Cannabidiol Oral Solution
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Radius Pharmaceuticals, Inc.